- cafead   Jan 13, 2023 at 11:02: AM
via New Biogen CEO Chris Viehbacher has set out plans for a subcutaneous version of lecanemab, outlining how changing the delivery method of the Eisai-partnered Alzheimer’s disease drug could be particularly valuable for pre-symptomatic patients.
article source
article source